During the coronavirus pandemic, states received a rush of funding from the federal government to bolster their fight against the disease. In many cases, that cash flowed into state and local health departments, fueling a staffing surge to handle, among other things, contact tracing and vaccination efforts. But public health leaders quickly identified a familiar…
Lynda Brown-Ganzert is CEO of RxPx. The company is the 2022 merger of the company she founded, Curatio, which was a support system for rare disease patients, with RxMx, a complementary service that helped clinicians manage patients on treatment or clinical trials. Lynda says that somehow I inspired the merger! (Although I don’t remember it,…
As hospitals face ongoing cost pressures and supply chain disruptions, Allina Health is redesigning its procurement strategy by moving away from a decentralized sourcing model and toward an approach that prioritizes governance and tech-driven efficiencies. Chief Supply Chain Officer Tom Lubotsky shared how the health system is saving money and boosting supply chain resilience. The…
AI can help health plans reduce friction, speed revenue-cycle throughput, and improve member experience, but only when it is deployed with strong data discipline, modern integration patterns, and a governance model that treats AI as “augmented intelligence,” meaning powerful, assistive, and accountable. The post From Claims Payer to Care Partner: What AI Really Changes in…
This brief highlights key facts about Medicare beneficiaries living in rural areas, including their demographic and health characteristics, access to care, and satisfaction with care.
Chris Darland is CEO of Peerbridge Health, which is the maker of a “3 lead to 12 lead” EKG patch that can give a better view of overall cardiac health than what’s on the market now–which tend to specialize in AFIB. Chris thinks that the Peerbridge Cor product will lead to a new world where…
This collection of charts explores the variation in health spending across the population through an analysis of 2023 Medical Expenditure Panel Survey (MEPS) data.
While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say. These officials were thrilled Oct. 29 when FDA Commissioner Marty Makary announced the…
Novartis’s Fabhalta is the first FDA-approved therapy for C3 glomerulopathy. But Apellis Pharmaceuticals’ Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy. The post Novartis Nabs First FDA Nod in Rare…
During cheerleading practice in April, Jana Duey’s sixth grade daughter, Karter, sustained a concussion when she fell several feet headfirst onto a gym floor mat. Days after, Karter still had a headache, dizziness, and sensitivity to light and noise. Karter rested for a week and a half at home in Centennial, Colorado, then returned to…